The discovery of genetic mapping led to a considerable expansion of medical data knowledge or ‘big data,’ which Foley partner Richard Kaufman suggests can be properly analyzed to improve drug discovery success and reduce the cost of developing a drug. He compares genetic mapping to an exquisite tailoring of one’s personal biology that holds the potential to make drugs developed using this data much more effective and ultimately may lead to better outcomes for patients.
People
Related News
April 17, 2026
In the News
Foley Moves Up to No. 43 on 2026 Am Law 100 List
Foley & Lardner LLP moved up two spots and is ranked as the No. 43 highest-grossing law firm on the 2026 Am Law 100, an annual report assessing the financial performance of the largest law firms in the United States.
April 15, 2026
In the News
Gregory Husisian Analyzes IEEPA Tariff Refund Rollout and CAPE Process
Foley & Lardner LLP partner Gregory Husisian is featured across media discussing recent developments regarding the initial phase of processing and distributing IEEPA tariff refunds.
April 15, 2026
In the News
Betsy Stone Honored Among Next Generation of Leaders at Women, Influence & Power in Law Awards
Foley & Lardner LLP senior counsel Betsy Stone was featured in Law.com as a Next Generation of Leaders at the 2026 Women, Influence & Power in Law Awards.